Luteolin for Brain Health & Neuroinflammation
Luteolin is one of the most studied flavones for brain inflammation, and it is also the topic where the gap between exciting laboratory findings and proven human benefit is widest. In cells and in animals, luteolin quiets activated microglia and mast cells — the brain's inflammatory first responders — and reduces the inflammatory messengers (interleukin-6 (IL-6), tumor necrosis factor-α, interleukin-1 beta (IL-1β)) linked to cognitive symptoms. That mechanistic story is genuinely strong. The human story is not: the clinical evidence is limited to a small number of open-label pilot studies, mostly of a luteolin-containing formulation in children with autism, with no large randomized controlled trials to confirm a benefit. This page lays out what the research actually shows, keeps the preclinical and clinical evidence clearly separated, and resists the temptation to oversell a promising but unproven story.
Table of Contents
- The Short, Honest Version
- Microglia: The Brain's Inflammatory First Responders
- Mast Cells in the Brain and the Blood-Brain Barrier
- The Autism Pilot Studies
- Brain Aging, Memory, and Senescent Microglia
- The “Brain Fog” Question
- Neurodegenerative Disease Research
- Mood and Depression Models
- What the Evidence Realistically Shows
- Key Research Papers
- Connections
- Featured Videos
The Short, Honest Version
This section is the summary. Luteolin has a well-documented ability to reduce inflammation in brain cells grown in a dish and in the brains of laboratory animals. The molecular pathways are clear and reproducible. But reducing inflammation in a mouse brain is not the same as improving memory, mood, or “brain fog” in a person, and the human trials that would prove such a benefit have not been done at the size or rigor needed.
What we can say fairly:
- Luteolin crosses into the brain to some degree and reaches concentrations that are biologically active in animal models.
- It reliably shifts microglia — the brain's immune cells — from an inflammatory to a quieter, more protective state.
- A small open-label pilot of a luteolin-containing supplement in children with autism reported behavioral improvements, but open-label pilots cannot separate a real drug effect from placebo and natural change.
- There are, as of this writing, no large placebo-controlled randomized trials showing that luteolin improves cognition, memory, or mood in adults.
So this is a page about a plausible and actively researched benefit, not an established one. That distinction matters, and we keep it visible throughout.
Microglia: The Brain's Inflammatory First Responders
Microglia are the resident immune cells of the brain. In a healthy resting state they act like caretakers — surveying tissue, pruning unused connections, and clearing debris. When they sense injury, infection, or the molecular signals of stress, they switch into an activated state and release inflammatory messengers. A short burst of this is protective. Chronic, low-grade microglial activation is increasingly implicated in cognitive decline, mood disorders, and the general fog that accompanies systemic inflammation.
Luteolin's single most reproducible brain effect is that it calms activated microglia. In a landmark 2008 study published in the Proceedings of the National Academy of Sciences, Jang and colleagues showed that luteolin reduced interleukin-6 (IL-6) production in microglia by blocking JNK phosphorylation and the activation of the AP-1 transcription factor — and that microglia treated this way no longer damaged neighboring neurons. In effect, luteolin interrupted the conversation by which an inflamed immune cell harms a nerve cell.
A 2010 study by Dirscherl and colleagues went further, mapping the entire microglial gene-expression program and finding that luteolin drove a “global” shift toward an anti-inflammatory, neuroprotective phenotype rather than tweaking a single pathway. This is why luteolin is often described as a broad microglial modulator: it does not just block one cytokine, it re-tunes the cell's whole inflammatory posture. Much of this converges on the same NF-κB and Nrf2 machinery discussed on the Antioxidant & Anti-Inflammatory page.
Mast Cells in the Brain and the Blood-Brain Barrier
Most people think of mast cells as the allergy cells that live in the skin and airways — and they are covered in detail on the Allergy & Mast Cells page. But mast cells also sit inside the brain, particularly around blood vessels and the regions that regulate mood and the stress response. When they degranulate, they release mediators that can increase the permeability of the blood-brain barrier and recruit and activate microglia.
Theoharides and colleagues have argued for two decades that this mast-cell–microglia axis is a shared driver across several brain conditions, and that luteolin is attractive precisely because it dampens both cell types at once. Their 2009 paper proposed luteolin as a therapeutic candidate for multiple sclerosis on this basis, and later work explored a more potent luteolin analog (tetramethoxyluteolin, abbreviated methlut) designed to be better absorbed and to reach the brain more effectively.
This is a mechanistically elegant idea with real preclinical support. It is worth stating plainly that a compelling mechanism has repeatedly failed to translate into human benefit for many candidate molecules in neurology, so a mechanism alone is grounds for curiosity, not confidence.
The Autism Pilot Studies
The most-cited human data on luteolin and the brain come from autism research. The reasoning is that a subset of children with autism spectrum disorder show markers of immune activation and mast-cell involvement, and that calming neuroinflammation might help behavioral symptoms in that subset.
In 2013, Taliou and colleagues published an open-label pilot study in Clinical Therapeutics: fifty children with autism (aged 4–10) were enrolled and forty completed 26 weeks of a luteolin-containing dietary formulation (luteolin 100 mg combined with the related flavonoid quercetin 70 mg and its glycoside rutin 30 mg per capsule, one capsule per 10 kg of body weight a day), and the researchers reported improvements in behavioral and adaptive measures. Age, sex and history of allergies had no effect on the results; the children's starting level of functioning or difficulty predicted the final outcome in most of the measures. Irritability increased for a time (1–8 weeks) in 27 of the 50 children.
A 2015 follow-up analysis by the same research group (Tsilioni and colleagues) reported reductions in inflammatory markers alongside the behavioral changes: mean blood (serum) levels of IL-6 and tumor necrosis factor (TNF) fell significantly by the end of the 26 weeks (P=0.036 and P=0.015), and these falls were strongly associated with the children whose behavior improved the most. Two stress-related messengers, corticotropin-releasing hormone (CRH) and neurotensin, did not change.
These findings are genuinely interesting, but the study design places hard limits on what they prove:
- Open-label — everyone knew they were getting the supplement, so expectation and placebo effects cannot be excluded, and parent-rated behavior is especially sensitive to expectation.
- No placebo control group — children develop over months regardless of treatment, so some improvement is expected simply from time.
- Small and selected — a few dozen children is a pilot, meant to justify a larger trial, not to establish efficacy.
- Combination product — luteolin was given with quercetin and other ingredients, so the effect cannot be attributed to luteolin specifically.
The honest summary is that these pilots were encouraging enough to warrant a properly controlled trial, but they are not evidence that luteolin treats autism, and no adequately powered randomized controlled trial has yet confirmed the signal. A 2023 systematic review of flavonoids in autism spectrum disorder (Savino and colleagues) found 17 preclinical studies and 4 clinical investigations; it reported that “there are no randomized placebo-controlled trials that support the clinical efficacy of flavonoids in ASD” (autism spectrum disorder), only open-label studies and case reports or series, all using luteolin and quercetin.
Brain Aging, Memory, and Senescent Microglia
A recurring theme in aging research is “inflammaging” the idea that a chronic, smoldering inflammatory tone accumulates with age and contributes to the slowing of memory and processing speed. In the brain, aged microglia become primed and over-reactive, producing more inflammatory cytokines in response to the same trigger.
Burton and colleagues (2016) fed dietary luteolin to aged mice for 4 weeks and found reduced proinflammatory microglial activity in the brain: in aged mice given a saline injection, the share of brain microglia staining for the inflammatory markers major histocompatibility complex (MHC) class II, IL-1β and IL-6 fell by nearly half (to 12%, 13% and 12%). Companion work from the same research group (Jang and colleagues, 2010) reported that dietary luteolin improved spatial working memory in aged mice and restored the expression of inflammatory markers in the hippocampus, the brain region central to memory; it had no effect on memory or those markers in young adult mice. These are consistent, biologically plausible results — and they are in mice. They support the hypothesis that reducing microglial inflammation could protect aging memory, but a mouse maze is not a human clinic, and the leap to “luteolin protects human memory” has not been made in controlled trials.
The “Brain Fog” Question
“Brain fog” the subjective sense of slowed, cloudy thinking — is a symptom, not a diagnosis, and it accompanies many conditions with an inflammatory component, including allergic and mast-cell disorders, post-viral fatigue states, and chronic stress. Because luteolin dampens exactly the mast-cell and microglial activity theorized to underlie inflammatory brain fog, it is frequently marketed for this use.
Here the evidence is at its thinnest. The mechanistic rationale is coherent, and some patients with mast-cell activation report symptom improvement with luteolin as part of a broader regimen (see Mast Cell Activation Syndrome and Natural Mast-Cell Stabilizers). But there is no controlled clinical trial demonstrating that luteolin relieves brain fog as an endpoint. Taking it for brain fog is an experiment with an uncertain outcome, not a proven remedy, and brain fog has many underlying causes, some of them treatable.
Neurodegenerative Disease Research
Luteolin has been tested in laboratory models of Alzheimer's disease, Parkinson's disease, and stroke, where it reduces markers of oxidative stress and neuroinflammation and, in some models, protects neurons from injury. Reviews such as Nabavi and colleagues (2015) and more recent syntheses catalog dozens of these preclinical reports and describe the shared mechanisms — Nrf2 activation, NF-κB suppression, and mitochondrial protection.
The crucial caveat is that every candidate anti-inflammatory has looked good in these same rodent models, and the overwhelming majority have failed in human neurodegeneration trials. Luteolin has not been tested in adequately powered human trials for Alzheimer's or Parkinson's disease. Presenting it as a treatment for these conditions would misrepresent the evidence. It is a plausible research candidate, nothing more; the tested care for these diagnoses is covered on the Alzheimer's Disease and Parkinson's Disease pages.
One small trial has tested luteolin, in combination, in another dementia. In a 2025 Phase 2 randomized, double-blind, placebo-controlled trial (Assogna and colleagues), 48 people with probable frontotemporal dementia took either palmitoylethanolamide combined with luteolin (700 mg + 70 mg twice a day, n = 25) or placebo (n = 23) for 24 weeks; 45 completed the study. The combination group showed less decline on the main dementia rating scale (the Clinical Dementia Rating with the National Alzheimer's Coordinating Center frontotemporal lobar degeneration module, sum of boxes; CDR plus NACC FTLD): an estimated mean change of 0.53, against 1.39 on placebo (P = 0.005). It also declined less on a daily-living scale and a language (aphasia) screening, and no effect was found on the other secondary measures. Because luteolin was given together with palmitoylethanolamide, the effect cannot be credited to luteolin alone.
Mood and Depression Models
Inflammation is one of the more robust biological correlates of depression, and a subset of people with depression have elevated inflammatory markers. This has made anti-inflammatory compounds a legitimate area of psychiatric research. In animal models of stress-induced depression — for example, chronic unpredictable mild stress paradigms — luteolin has reduced depressive-like behaviors while lowering neuroinflammatory signaling.
These are, again, animal findings. They contribute to the broader “inflammation and mood” research program but do not establish luteolin as an antidepressant. There is no controlled human trial of luteolin for depression, and depression is a serious condition with treatments that have been tested in human trials, which luteolin has not.
What the Evidence Realistically Shows
- Strong mechanism, weak clinical proof. The cell and animal biology of luteolin in the brain is genuinely impressive and reproducible; the human evidence is limited to small, mostly open-label pilots.
- The best human signal is in autism — and even that is a pilot-level, uncontrolled, combination-product result that needs a randomized trial before it means anything definite.
- “Brain fog,” memory, mood, and neurodegeneration claims are hypotheses, supported by mechanism and animal data, not by human trials.
- Luteolin for a cognitive symptom is an untested use. For an inflammatory or mast-cell-related cognitive symptom, taking it amounts to an informed experiment with modest expectations; it does not replace finding and treating the underlying condition.
- Food-level luteolin from a plant-rich diet is safe and carries the general benefits of a flavonoid-rich diet; that is a reasonable baseline regardless of the brain-specific claims.
Key Research Papers
- Jang S et al. (2008). Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. Proceedings of the National Academy of Sciences — PubMed PMID: 18490655
- Dirscherl K et al. (2010). Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. Journal of Neuroinflammation — PubMed PMID: 20074346
- Theoharides TC (2009). Luteolin as a therapeutic option for multiple sclerosis. Journal of Neuroinflammation — PubMed PMID: 19825165
- Taliou A et al. (2013). An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clinical Therapeutics — PubMed PMID: 23688534
- Burton MD et al. (2016). Dietary Luteolin Reduces Proinflammatory Microglia in the Brain of Senescent Mice. Rejuvenation Research — PubMed PMID: 26918466
- Theoharides TC, Tsilioni I (2018). Tetramethoxyluteolin for the Treatment of Neurodegenerative Diseases. Current Topics in Medicinal Chemistry — PubMed PMID: 30451113
- Theoharides TC et al. (2019). Recent advances in our understanding of mast cell activation. Expert Review of Clinical Immunology — PubMed PMID: 30884251
- Nabavi SF et al. (2015). Luteolin as an anti-inflammatory and neuroprotective agent: A brief review. Brain Research Bulletin — PubMed PMID: 26361743
- Tan X et al. (2019). Luteolin Exerts Neuroprotection via Modulation of the p62/Keap1/Nrf2 Pathway in Intracerebral Hemorrhage. Frontiers in Pharmacology — PubMed PMID: 32038239
- Mahto K et al. (2025). Therapeutic potential of luteolin in neurodegenerative disorders: targeting Nrf2, NF-κB. Inflammopharmacology — PubMed PMID: 40694206
- Wu HH et al. (2025). Luteolin alleviates CUMS-induced depressive-like behavioral deficits in mice through blocking the JAK2/STAT3 pathway. PLoS One — PubMed PMID: 41134796
- Jang S, Dilger RN, Johnson RW (2010). Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice. Journal of Nutrition — PubMed PMID: 20685893
- Tsilioni I, Taliou A, Francis K, Theoharides TC (2015). Children with autism spectrum disorders, who improved with a luteolin-containing dietary formulation, show reduced serum levels of TNF and IL-6. Translational Psychiatry — PubMed PMID: 26418275
- Savino R, Medoro A, Ali S, et al. (2023). The Emerging Role of Flavonoids in Autism Spectrum Disorder: A Systematic Review. Journal of Clinical Medicine — PubMed PMID: 37240625
- Assogna M, Di Lorenzo F, Bonnì S, et al. (2025). Phase 2 study of palmitoylethanolamide combined with luteoline in frontotemporal dementia patients. Brain Communications — PubMed PMID: 40046339